About this trial
Neuropathic pain affects 6-10% of the global population and is poorly managed - current drug treatments succeed in only \~25% of patients. Spinal cord stimulation (SCS) modulates pain by electrically stimulating spinal dorsal column fibres. The newer paresthesia-free mode (PF-SCS, 500-10,000 Hz) appears more effective and tolerable than traditional paresthesia-based SCS, with superior outcomes shown in the SENZA-RCT. All promising PF-SCS studies have been unblinded, making them susceptible to placebo effects. The one blinded RCT that exists had significant methodological flaws (no washout period, single baseline measurement) that biased results toward the null. A blinded, multi-centre, crossover RCT in 90 patients comparing 6 weeks of active PF-SCS vs. 6 weeks of placebo stimulation, with a 2-week washout in between - designed to correct the flaws of the prior trial and definitively establish whether PF-SCS works beyond placebo.
Eligibility criteria
Qualifiers
Age 18 years or older
Severe NP in the axial locations (neck and back) and/ or the limbs
Undergoing an SCS implantation with a PF device
Disqualifiers
Previously implanted with an SCS device
Not fluent in English
Unable to provide written informed consent
Trial design
Treatments tested in this trial
- Paresthesia-free spinal cord stimulation
Treatment groups
Locations
Sponsors and collaborators
University Health Network, Toronto
Lead sponsor